IMMP Immutep Limited

1.9
0  0%
Previous Close 1.9
Open 1.95
Price To Book 3.88
Market Cap 6,482,374
Shares 3,411,776
Volume 7,627
Short Ratio
Av. Daily Volume 45,357
Stock charts supplied by TradingView

NewsSee all news

  1. Immutep Presents Positive Interim Data From Phase II TACTI-002 Trial at SITC

    Part A comprises NSCLC patients with all levels of PD-L1 expression, being an all comer trialPreliminary Overall Response Rate (ORR) of 41% from stage 11 of Part A  ORR compares favourably to standard of care treatments

  2. Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma

    Key Trial Findings Favourable safety profile of eftilagimod alpha in combination with pembrolizumabDeep and durable responses have been observed with tumour shrinkage in 56% and 66% of patients in part A and B

  3. Immutep Receives A$2.5 Million R&D Tax Incentive from French Government

    SYDNEY, Australia, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and

  4. Immutep Announces Data Presentations at Upcoming Industry Conferences

    SYDNEY, Australia, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and

  5. Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data

    Requisite clinical responses achieved in cohort 1 of Part A (1st line NSCLC) of TACTI-002 Phase II clinical trial to allow for recruitment of cohort 2Recruitment of cohort 2 of Part A of TACTI-002, additional 19

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b PFS data due 1Q 2020.
Eftilagimod Alpha - Active Immunotherapy PAClitaxel (AIPAC)
Metastatic breast cancer (MBC)
Phase 1 final safety data due 1H 2020.
Eftilagimod alpha and Keytruda (TACTI-mel)
Melanoma
Phase 2 data due 1Q 2020.
Eftilagimod alpha and Keytruda - TACTI-002
Non-small cell lung cancer; Head and neck cancer
Phase 1 initial data due 4Q 2019.
Eftilagimod alpha - INSIGHT-004
Solid tumors
Phase 2 data due early 2022.
GSK2831781
Ulcerative Colitis

Latest News

  1. Immutep Presents Positive Interim Data From Phase II TACTI-002 Trial at SITC

    Part A comprises NSCLC patients with all levels of PD-L1 expression, being an all comer trialPreliminary Overall Response Rate (ORR) of 41% from stage 11 of Part A  ORR compares favourably to standard of care treatments

  2. Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma

    Key Trial Findings Favourable safety profile of eftilagimod alpha in combination with pembrolizumabDeep and durable responses have been observed with tumour shrinkage in 56% and 66% of patients in part A and B

  3. Immutep Receives A$2.5 Million R&D Tax Incentive from French Government

    SYDNEY, Australia, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and

  4. Immutep Announces Data Presentations at Upcoming Industry Conferences

    SYDNEY, Australia, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and

  5. Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data

    Requisite clinical responses achieved in cohort 1 of Part A (1st line NSCLC) of TACTI-002 Phase II clinical trial to allow for recruitment of cohort 2Recruitment of cohort 2 of Part A of TACTI-002, additional 19

  6. Immutep to Receive £4M Milestone Payment From GSK

    SYDNEY, Australia, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and

  7. Immutep Announces Japanese Patent Grant for LAG525 Antibody

    SYDNEY, Australia, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company") is pleased to announce the grant of patent no. 6576962 entitled "Antibody molecules to

  8. Immutep Granted European Patent for Eftilagimod Alpha in Cancer

    SYDNEY, Australia, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and